Clinical application of a glucoside-hydrolase inhibitor (Bay g 5421) to patients with hyperlipidemia and maturity-onset type diabetes mellitus.

DOI Web Site Web Site 1 Citations
  • MARUHAMA YOSHISUKE
    Department of Internal Medicine, Tohoku University School of Medicine
  • GOTO YOSHIO
    Department of Internal Medicine, Tohoku University School of Medicine

Bibliographic Information

Other Title
  • Clinical Application of a Glucoside Hyd

Search this article

Description

Administration of Bay g 5421, a glucoside-hydrolase inhibiting oligosaccharide, was shown to decrease the elevation of blood glucose and plasma insulin after test meal ingestion in 2 healthy volunteers by delaying the rate of the starch absorption that was estimated by the serial breath hydrogen analysis. The clinical trial was carried out on 9 hyperlipidemic patients and 6 diabetic patients with a daily dosage of 300 mg of Bay g 5421 for 4 weeks. A significant decrease in plasma triglyceride and total cholesterol was observed in both hyperlipidemics and diabetics, while their body weight remained mostly unchanged. Both mild glucose intolerance and markedly increased insulin response during oral glucose tolerance test in the hyperlipidemics were significantly ameliorated after Bay g 5421 trial, whereas the diabetic glucose intolerance and blunted insulin secretion did not change significantly in the diabetics after the trial. Thus, Bay g 5421 seems to be the compound that is clinically more beneficial in hyperlipidemia rather than in diabetes mellitus.

Journal

Citations (1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top